Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Toronto
$120,000.00
Predictors of Antidepressant Response of Psilocybin-Assisted Psychotherapy for Treatment Resistant Depression
FY 2025-26
Summary
Background: Depression affects millions of people globally, but around 30% of people with depression will not improve with regular antidepressant medications, termed treatment-resistant depression (TRD). TRD is linked to more severe depression symptoms, reduced rates of recovery and greater challenges to everyday functioning. Recently, psilocybin, the active compound in "magic mushrooms," has been shown to relieve symptoms of depression, including TRD, when combined with psychotherapy ("psilocybin-assisted therapy"; PAT). However, as PAT is expensive and time consuming, there is a need to find ways of predicting which depression patients is more likely to benefit from this treatment
Objectives: Our goal is to find out what factors, such as age, gender, how severe their depression is, past treatments, intensity of psychedelic effects, can help predict how likely it is that PAT will help them and how much it may help.
Methods: In this study, one group of 46 participants will receive one low dose (placebo, 1 mg) and one high dose (25 mg) of psilocybin, while the other group will receive two high doses of psilocybin. We will measure depression symptoms over time for the 8-week study and for 6-months of follow-up. We will also measure the intensity of mystical and psychedelic effects and experiences after each dosing session.
Anticipated Results: We expect to find variables, patient expectations of PAT quality of rapport with the therapist, and recent antidepressant medication use that will predict the likelihood of improvements in depression symptoms after PAT.
Significance: Currently, there is not reliable research on predicting who will improve in depression symptoms with PAT. The studies that do exist are relatively smaller and typically have only focused on using brain scans or the intensity of psychedelic effects to predict response. As PAT becomes more common in clinical research, it is important to determine how we can make it work better and more safely.
Department
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
559640
Name
Chisamore Noah
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Predictors of Antidepressant Response of Psilocybin-Assisted Psychotherapy for Treatment Resistant Depression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Psilocybin; Psilocybin-Assisted Psychotherapy; Randomized Controlled Trial; Treatment-Resistant Depression
Abstract
Background: Depression affects millions of people globally, but around 30% of people with depression will not improve with regular antidepressant medications, termed treatment-resistant depression (TRD). TRD is linked to more severe depression symptoms, reduced rates of recovery and greater challenges to everyday functioning. Recently, psilocybin, the active compound in "magic mushrooms," has been shown to relieve symptoms of depression, including TRD, when combined with psychotherapy ("psilocybin-assisted therapy"; PAT). However, as PAT is expensive and time consuming, there is a need to find ways of predicting which depression patients is more likely to benefit from this treatment
Objectives: Our goal is to find out what factors, such as age, gender, how severe their depression is, past treatments, intensity of psychedelic effects, can help predict how likely it is that PAT will help them and how much it may help.
Methods: In this study, one group of 46 participants will receive one low dose (placebo, 1 mg) and one high dose (25 mg) of psilocybin, while the other group will receive two high doses of psilocybin. We will measure depression symptoms over time for the 8-week study and for 6-months of follow-up. We will also measure the intensity of mystical and psychedelic effects and experiences after each dosing session.
Anticipated Results: We expect to find variables, patient expectations of PAT quality of rapport with the therapist, and recent antidepressant medication use that will predict the likelihood of improvements in depression symptoms after PAT.
Significance: Currently, there is not reliable research on predicting who will improve in depression symptoms with PAT. The studies that do exist are relatively smaller and typically have only focused on using brain scans or the intensity of psychedelic effects to predict response. As PAT becomes more common in clinical research, it is important to determine how we can make it work better and more safely.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chisamore, Noah
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~